- Home
- DCBO vs IMTX Comparison
DCBO vs IMTX Comparison
Compare DCBO & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCBO
- IMTX
- Stock Information
- Founded
- DCBO 2016
- IMTX N/A
- Country
- DCBO Canada
- IMTX Germany
- Employees
- DCBO N/A
- IMTX N/A
- Industry
- DCBO
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DCBO
- IMTX Health Care
- Exchange
- DCBO Nasdaq
- IMTX Nasdaq
- Market Cap
- DCBO 793.9M
- IMTX 653.9M
- IPO Year
- DCBO 2020
- IMTX N/A
- Fundamental
- Price
- DCBO $28.90
- IMTX $6.11
- Analyst Decision
- DCBO Strong Buy
- IMTX Strong Buy
- Analyst Count
- DCBO 5
- IMTX 4
- Target Price
- DCBO $42.20
- IMTX $14.67
- AVG Volume (30 Days)
- DCBO 69.5K
- IMTX 637.2K
- Earning Date
- DCBO 08-08-2025
- IMTX 08-12-2025
- Dividend Yield
- DCBO N/A
- IMTX N/A
- EPS Growth
- DCBO 268.72
- IMTX N/A
- EPS
- DCBO 0.74
- IMTX N/A
- Revenue
- DCBO $222,824,000.00
- IMTX $155,801,989.00
- Revenue This Year
- DCBO $13.57
- IMTX N/A
- Revenue Next Year
- DCBO $13.40
- IMTX $1.92
- P/E Ratio
- DCBO $36.59
- IMTX N/A
- Revenue Growth
- DCBO 16.79
- IMTX 93.56
- 52 Week Low
- DCBO $25.50
- IMTX $3.30
- 52 Week High
- DCBO $53.86
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- DCBO 52.83
- IMTX 63.27
- Support Level
- DCBO $27.80
- IMTX $5.50
- Resistance Level
- DCBO $29.61
- IMTX $6.17
- Average True Range (ATR)
- DCBO 0.72
- IMTX 0.27
- MACD
- DCBO 0.14
- IMTX 0.03
- Stochastic Oscillator
- DCBO 68.84
- IMTX 93.62
About DCBO Docebo Inc.
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.